1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow David Oh: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Atezolizumab, Tocilizumab, Etrumadenant - Prostate Adenocarcinoma, Prostate Cancer | Phase 2 | Recruiting | David Oh | 68 | 2019-10-30 | 2026-06-04 |
| Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT Pembrolizumab, SD-101, Leuprolide acetate - Prostatic Neoplasms | Phase 2 | Completed | David Oh | 23 | 2017-05-17 | 2025-12-05 |
Abiraterone Acetate (1) · Leuprolide (1) · Prednisone (1) · Radiosurgery (1) · Toll-Like Receptor 9 (1) · atezolizumab (1) · pembrolizumab (1) · tocilizumab (1)
United States (2)